Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products.
Read More…
Industry, Sector and Symbol
Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
Phone508-263-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees6,252
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Hologic (NASDAQ:HOLX) Frequently Asked Questions
What is Hologic's stock symbol?
Hologic trades on the NASDAQ under the ticker symbol "HOLX."
How were Hologic's earnings last quarter?
Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Wednesday, July, 31st. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.61 by $0.02. The medical equipment provider had revenue of $852.40 million for the quarter, compared to analyst estimates of $836.91 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The firm's revenue was up 3.4% compared to the same quarter last year. During the same period last year, the company posted $0.58 earnings per share. View Hologic's Earnings History.
When is Hologic's next earnings date?
What guidance has Hologic issued on next quarter's earnings?
Hologic issued an update on its fourth quarter earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus estimate of $0.66. The company issued revenue guidance of $834-839 million, compared to the consensus revenue estimate of $850.36 million.
What price target have analysts set for HOLX?
10 brokers have issued 12-month target prices for Hologic's stock. Their forecasts range from $38.28 to $62.00. On average, they anticipate Hologic's stock price to reach $49.7280 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Hologic.
What is the consensus analysts' recommendation for Hologic?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hologic.
What are Wall Street analysts saying about Hologic stock?
Here are some recent quotes from research analysts about Hologic stock:
- 1. According to Zacks Investment Research, "Hologic exited the third quarter of fiscal 2019 on a solid note. The company registered strong top-line growth driven by solid increase in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima BV and Aptima CV/TV assays in the United States, the Trident HD specimen radiography system in the United States, Europe and Canada, and ThinPrep Genesis processor for cytology slide and molecular test preparation in Europe. Hologic has outperformed its industry over the past three months. On the flip side, foreign exchange headwind got intense during the quarter. Further, both the company’s margins contracted in the quarter under review. This apart volume environment for testing laboratories and utilization weaknesses are looming headwinds." (8/16/2019)
- 2. Canaccord Genuity analysts commented, "We look for greater evidence for Hologic to find a solution to its declining gross margins and we need more time to get confident that Cynosure has bottomed. Nevertheless, near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide. That said, its FY’19 raised" revenue is less than the FQ3 $17M beat (FX headwinds being one factor), a consistent trend of setting a low bar for the next reporting quarter and essentially not raising its underlying baseline guide. We reiterate our HOLD, PT to $52. FQ3 beat. (+3.4% rep, +4.7% FXN) exceeded our/Street’s $835ME and adj." (8/1/2019)
- 3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet." (7/10/2019)
Has Hologic been receiving favorable news coverage?
News stories about HOLX stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hologic earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Hologic.
Who are some of Hologic's key competitors?
Some companies that are related to Hologic include Vertex Pharmaceuticals (VRTX), Illumina (ILMN), Edwards Lifesciences (EW), Baxter International (BAX), Biogen (BIIB), HCA Healthcare (HCA), Humana (HUM), Siemens Healthineers (SHL), ESSILOR INTL S/S (ESLOY), Regeneron Pharmaceuticals (REGN), Actelion (ALIOF), Zimmer Biomet (ZBH), Takeda Pharmaceutical (TKPYY), RESMED/IDR UNRESTR (RMD) and ASTELLAS PHARMA/ADR (ALPMY).
What other stocks do shareholders of Hologic own?
Who are Hologic's key executives?
Hologic's management team includes the folowing people:
- Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
- Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
- Mr. John M. Griffin, Gen. Counsel (Age 58)
- Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
- Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)
Who are Hologic's major shareholders?
Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (15.79%), Vanguard Group Inc. (11.30%), BlackRock Inc. (6.96%), BlackRock Inc. (6.96%), Parnassus Investments CA (5.81%) and Nuveen Asset Management LLC (1.98%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Christiana Stamoulis, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Institutional Ownership Trends for Hologic.
Which institutional investors are selling Hologic stock?
HOLX stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Pictet Asset Management Ltd., Vanguard Group Inc., Los Angeles Capital Management & Equity Research Inc., JPMorgan Chase & Co., Wedge Capital Management L L P NC, Parnassus Investments CA and Swiss National Bank. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Insider Buying and Selling for Hologic.
Which institutional investors are buying Hologic stock?
HOLX stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Point72 Asset Management L.P., Charles Schwab Investment Management Inc., AQR Capital Management LLC, Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Man Group plc and Atwood & Palmer Inc.. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.
How do I buy shares of Hologic?
Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hologic's stock price today?
One share of HOLX stock can currently be purchased for approximately $49.95.
How big of a company is Hologic?
Hologic has a market capitalization of $13.35 billion and generates $3.22 billion in revenue each year. The medical equipment provider earns $-111,300,000.00 in net income (profit) each year or $2.23 on an earnings per share basis. Hologic employs 6,252 workers across the globe.View Additional Information About Hologic.
What is Hologic's official website?
How can I contact Hologic?
Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]
MarketBeat Community Rating for Hologic (NASDAQ HOLX)
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
